About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
InventisBio image

InventisBio

Summary
History
Mission
Vision
References
Summaryarrow
InventisBio Co., Ltd., a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer, etc. indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications. The company has a collaboration agreement with Betta Pharma to out-license D-0316's right in China to Betta Pharma; and to co-develop it in China. InventisBio Co., Ltd. was founded in 2013 and is headquartered in Pudong, China.
Historyarrow

InventisBio was founded in 2015 in Boston, Massachusetts. We have grown to be a dynamic and innovative leader in the life sciences industry, with a strong focus on leveraging cutting-edge technology to develop products and solutions that will be beneficial to both researchers and patients. We are dedicated to fostering innovation in the field of biomedical research and providing our customers with high-quality resources and services.

Missionarrow
Our mission is to provide innovative products that drive life science research and patient health outcomes. We are dedicated to delivering timely, accurate and reliable products and services that will improve the quality of life. Furthermore, we are committed to empowering people to achieve their full potential and positively impacting our community by creating jobs and opportunities for growth.
Visionarrow
Our vision is to revolutionize biomedical research and patient care by leveraging data-driven insights and cutting-edge technology. We are committed to delivering tailored solutions and technologies to our customers that will revolutionize the way healthcare is delivered.
Referencesarrow

https://in.investing.com/equities/inventisbio

https://finance.yahoo.com/quote/688382.SS/profile?p=688382.SS

https://www.crunchbase.com/organization/inventisbio-2

https://www.inventisbio.com

Share

Leadership team
D
Dr. Yaolin Wang (CEO & Chairman)
M
Mr. Xing Dai (Director and Deputy Gen. Mang.)
Products / Services
Biopharma, Biotechnology, Pharmaceutical
Number of Employees
0 - 50
Address
Shanghai, Shanghai, China
Established
2013-01-01
Traded as
SSE:688382
Website
https://www.inventisbio.com
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo